Literature DB >> 13129798

Riluzole for ALS: what is the evidence?

Robert Miller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 13129798

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord        ISSN： 1466-0822


× No keyword cloud information.
  7 in total

1.  The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells.

Authors:  Maithao N Le; Joseph L-K Chan; Stephen A Rosenberg; Adam S Nabatian; Kim T Merrigan; Karine A Cohen-Solal; James S Goydos
Journal:  J Invest Dermatol       Date:  2010-05-27       Impact factor: 8.551

2.  Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo.

Authors:  Atif J Khan; Brian Wall; Stuti Ahlawat; Camille Green; Devora Schiff; Janice M Mehnert; James S Goydos; Suzie Chen; Bruce G Haffty
Journal:  Clin Cancer Res       Date:  2011-02-15       Impact factor: 12.531

3.  A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma.

Authors:  Dana Yip; Maithao N Le; Joseph L-K Chan; Jonathan H Lee; Janice A Mehnert; Anthony Yudd; Jeffery Kempf; Weichung J Shih; Suzie Chen; James S Goydos
Journal:  Clin Cancer Res       Date:  2009-05-19       Impact factor: 12.531

4.  A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma.

Authors:  Janice M Mehnert; Ann W Silk; J H Lee; Liesel Dudek; Byeong-Seon Jeong; Jiadong Li; Jason M Schenkel; Evita Sadimin; Michael Kane; Hongxia Lin; Weichung J Shih; Andrew Zloza; Suzie Chen; James S Goydos
Journal:  Pigment Cell Melanoma Res       Date:  2018-04-10       Impact factor: 4.693

5.  The glutamate release inhibitor riluzole increases DNA damage and enhances cytotoxicity in human glioma cells, in vitro and in vivo.

Authors:  Atif J Khan; Stephanie LaCava; Monal Mehta; Devora Schiff; Aditya Thandoni; Sachin Jhawar; Shabbar Danish; Bruce G Haffty; Suzie Chen
Journal:  Oncotarget       Date:  2019-04-19

6.  Structural Dynamics of Human Argonaute2 and Its Interaction with siRNAs Designed to Target Mutant tdp43.

Authors:  Vishwambhar Bhandare; Amutha Ramaswamy
Journal:  Adv Bioinformatics       Date:  2016-03-06

7.  Repurposing Potential of Riluzole as an ITAF Inhibitor in mTOR Therapy Resistant Glioblastoma.

Authors:  Angelica Benavides-Serrato; Jacquelyn T Saunders; Brent Holmes; Robert N Nishimura; Alan Lichtenstein; Joseph Gera
Journal:  Int J Mol Sci       Date:  2020-01-05       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.